Abstract
Antiholinergic drugs remain the most popular treatment of the low urinary tract dysfunction in patients with multiple sclerosis, but often they are not effective or followed by marked side effects. Moreover, the evidence for their efficacy in multiple sclerosis is quite poor. In the review, the efficiency and safety of botulinumtoxin for neurogenic low urinary tract dysfunction in multiple sclerosis patients were analyzed according to the literature database.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
